Upgraded to a "BUY" this week by ML/Bank of America.
Afrezza has the potential to be the next blockbuster drug in the treatment of diabetes.
Mannkind is expected to have a "big pharma" marketing partnership in place to launch Afrezza.
Currently trading under $2.00.
Take a look at SRPT. Something's UP. BO?
Afrezza's approval run-up is due to start soon.
Get in under $2.00.